We describe a combined HPLC-RIA technique to measure both major metabolites of prostacyclin (PG12): 6-keto PGFIa and 2,3-dinor-6 keto PGF1a. The measurement of the former, which originates from renal blood vessels, and the latter, from systemic vessels and the liver, may provide a better overall evaluation of production than measurement of one metabolite. An aliquot of acidified urine with added 3H-labeled metabolites is adsorbed and then eluted from a C,8 Bond-Elut column. The sample is then passed through an HPLC system by use of an isocratic solvent combination that separates the two metabolites from known prostaglandins. [5,8,9,11,12,14,15-3H] 
12 and 250 pg of either metabolite, with high accuracy and precision (CV5 of 12% for a low concentration and 7% for a high concentration). Reference values for apparently healthy subjects were, respectively, 107 (SD 45) and 171 (SD 69) ng/g creatinine for 6-keto PGFIa and the dinor metabolite in men (n = 18) and 45 (SD 22) and 141 (SD 28) ng/g creatinine, respectively, in women (n = 15). Indomethacin in standard doses reduced both metabolite values by 50%. Intravenous administration of angiotensin II (5 ng/kg of body wt per minute) did not alter excretion rates, but equipressor doses of norepinephrine (0.1 pg/kg per minute) increased the production of both metabolites (6-keto >dinor). [5,8,9,11,12,14,15-3H] however, the a adrenergic agonist norepinephrine stimulates the synthesis and release of PG!2. This assay, which can be set up in many laboratories, should expand and encourage the evaluation of prostacyclmn in vascular and renal disorders. 
